ERBB2 and breast cancer: Brain metastasis was identified in 20 patients (1.9%) and was distributed in different rates according to the intrinsic breast cancer subtypes, i.e., 1.2% (n = 2) in Her2-enriched, 1.7% (n = 2) in luminal B-like, 2.06% (n = 10) in luminal A-like, and 2.1% (n = 6) in TNBC.